scholarly journals Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis

2016 ◽  
Vol 151 (1) ◽  
pp. 87-96.e6 ◽  
Author(s):  
Anthony Lembo ◽  
Michael Camilleri ◽  
Richard McCallum ◽  
Ramon Sastre ◽  
Cristian Breton ◽  
...  
2014 ◽  
Vol 32 (2) ◽  
pp. 139-145 ◽  
Author(s):  
Netanella Danielli Miller ◽  
Elad Schiff ◽  
Eran Ben-Arye ◽  
Joelle Singer ◽  
Tsachi Tsadok Perets ◽  
...  

Objectives The aim of this preliminary study was to compare the effectiveness of domperidone and acupuncture for the management of diabetic gastroparesis. Methods This was a preliminary, prospective non-randomised, unblinded case-crossover study conducted in patients with longstanding, uncontrolled diabetes mellitus and gastroparesis. All patients received domperidone (20 mg four times a day) for 12 weeks, followed by a 2–3 week washout period, and then biweekly acupuncture treatments for 8 weeks. Gastric emptying rate, glucose and glycated haemoglobin (HbA1C) levels were measured at start and end of each treatment period. At each of these timepoints patients completed the Gastroparesis Cardinal Symptom Index (GCSI), the Satisfaction with Life Scale (SWLS), and the Short-Form 36 Health Survey Update (SF-36). Results The trial was curtailed after only eight participants could be recruited in 3 years. The mean age of patients was 57.1±9.9 years, the male:female ratio was 1:7 and mean body mass index (kg/m2) was 25.2±1.2. There was no change in any of the outcome parameters after treatment with domperidone. Acupuncture was associated with a decrease in scores for almost all cardinal symptoms of the GCSI, as well as in increased total score on the SWLS (p=0.002) and the social functioning domain of the SF-36 (p=0.054). Acupuncture did not lead to an improvement in gastric emptying, or glucose control from baseline. Conclusions Acupuncture treatment may lead to symptomatic improvement in patients with diabetic gastroparesis. Within the limitations of this preliminary, non-randomised and unblinded study, it appears that this effect may be due to non-specific mechanisms.


2009 ◽  
Vol 45 (3) ◽  
pp. 175
Author(s):  
Kyung-Ju Lee ◽  
Kyoung-Ho Ryu ◽  
Jin-Ook Chung ◽  
Dong-Hyeok Cho ◽  
Dong-Jin Chung ◽  
...  

2004 ◽  
Vol 20 (3) ◽  
pp. 333-338 ◽  
Author(s):  
A. Russo ◽  
J. E. Stevens ◽  
N. Giles ◽  
G. Krause ◽  
D. G. O'Donovan ◽  
...  

2005 ◽  
Vol 100 ◽  
pp. S325 ◽  
Author(s):  
Jean-Rene Basque ◽  
Y. Kikuchi ◽  
T. Ohtsubo ◽  
G. Sarashina ◽  
H. Nakamura

1985 ◽  
Vol 289 (6) ◽  
pp. 240-242 ◽  
Author(s):  
Richard A. Wright ◽  
Rosa Clemente ◽  
Ronald Wathen

2004 ◽  
Vol 287 (3) ◽  
pp. G612-G619 ◽  
Author(s):  
Arlene N. James ◽  
James P. Ryan ◽  
Michael D. Crowell ◽  
Henry P. Parkman

The C57BLKS/J db/ db mouse develops hyperglycemia and has delayed gastric emptying that is improved with tegaserod, a partial 5-HT4 agonist. Our aims here were to determine regional gastric contractility alterations in C57BLKS/J db/ db mice and to determine the effects of serotonin and tegaserod. The contractile effects of bethanechol, serotonin, and tegaserod in fundic, antral, and pyloric circular muscle were compared in C57BLKS/J db/ db mice and normal littermates. The effects of tetrodotoxin, atropine, and 5-HT receptor antagonists were studied. Contractions in response to bethanechol were decreased in the fundus, similar in the antrum, but increased in the pylorus in diabetic mice compared with controls. Serotonin and, to a lesser extent, tegaserod caused contractions that were more pronounced in the fundus than in the antrum and pylorus in both diabetic and normal mice. Serotonin-induced contractions were partially inhibited by atropine, the 5-HT4 antagonist GR113808, and the 5-HT2 antagonist cinanseron but not tetrodotoxin. Regional gastric contractility alterations are present in this diabetic gastroparesis mouse model. Fundic contractility was decreased, but pyloric contractility was increased in the pylorus to cholinergic stimulation in diabetic mice. Serotonin's contractile effect is mediated, in part, through muscarinic, 5-HT2, and 5-HT4 receptors. This study suggests that fundic hypomotility and pyloric hypercontractility, rather than antral hypomotility, play important roles for the gastric dysmotility that occurs in diabetes.


2010 ◽  
Vol 298 (6) ◽  
pp. G1013-G1019 ◽  
Author(s):  
Purna C. Kashyap ◽  
Kyoung Moo Choi ◽  
Nirjhar Dutta ◽  
David R. Linden ◽  
Joseph H. Szurszewski ◽  
...  

Diabetic gastroparesis is associated with increased oxidative stress attributable to loss of upregulation of heme oxygenase-1 (HO1), with resultant damage to interstitial cells of Cajal and delayed gastric emptying. These changes can be reversed by induction of HO1. HO1 catalyzes the breakdown of heme into iron, biliverdin and, carbon monoxide (CO). The aim of this study was to determine whether inhalation of CO can mimic the protective effects of HO1. Nonobese diabetic (NOD) mice with delayed gastric emptying were treated with CO inhalation. Serum malondialdehyde was measured as a marker of oxidative stress. Gastric emptying of solids was measured using a [13C]octanoic acid breath test. Kit expression levels were determined in immunoblots of protein extracted from the external muscle layers of the gastric body and antrum. The effect of CO on oxidative stress and gastric emptying was also determined in the presence of HO activity inhibitor chromium mesoporphyrin. CO inhalation reduced oxidative stress, restored Kit expression and reversed delayed gastric emptying in diabetic NOD mice with delayed gastric emptying. CO inhalation maintained this effect in the presence of the HO activity inhibitor, chromium mesoporphyrin, also resulting in restoration of the delay in gastric emptying. CO inhalation mimics the protective effect of upregulation of HO1 and decreased oxidative stress, increased Kit expression, and restored delay in gastric emptying. This effect of CO was independent of HO activity, suggesting that its effects were downstream of HO1. CO represents a potential therapeutic option for treatment of diabetic gastroparesis.


2017 ◽  
Vol 152 (5) ◽  
pp. S519-S520
Author(s):  
Subhankar Chakraborty ◽  
Magnus Halland ◽  
Phillip A. Low ◽  
Michael Camilleri ◽  
Kelly Feuerhak ◽  
...  

1995 ◽  
Vol 40 (1) ◽  
pp. 141-146 ◽  
Author(s):  
Steven G. Desautels ◽  
William R. Hutson ◽  
Paul E. Christian ◽  
John G. Moore ◽  
Fred L. Datz

Sign in / Sign up

Export Citation Format

Share Document